Skip to main content
. 2020 May 10;10(5):e036827. doi: 10.1136/bmjopen-2020-036827

Table 2.

Baseline echocardiographic variables of patients with progression, stabilisation and regression of rheumatic heart disease at 2-year follow-up

Valve Variable* Progressed: borderline to definite (N=29) Remained definite (N=11) Regressed/stable (borderline)/other (N=156)
Mitral valve, N (%) Anterior leaflet thickening† 18 (62.1) 10 (90.9) 103 (65.6)
Chordal thickening 0 2 (18.2) 0
Restricted leaflet motion 1 (3.4) 4 (36.4) 4 (2.5)
Excessive leaflet tip motion 2 (6.9) 6 (54.5) 20 (12.7)
Mitral stenosis 0 0 0
Any regurgitation 28 (96.6) 11 (100) 141 (90.4)
Regurgitation seen in two views 26 (89.7) 10 (90.9) 141 (90.4)
Jet length ≥2 cm‡ 25 (86.2) 9 (81.8) 116 (74.4)
Velocity ≥3 m/s for one envelope§ 9 (31.0) 4 (36.4) 32 (20.5)
Pansystolic jet (colour Doppler) 15 (51.7) 8 (72.7) 99 (63.5)
Aortic valve, N (%) Irregular or focal thickening 0 2 (18.2) 1 (0.6)
Coaptation defect 0 1 (9.1) 2 (1.3)
Restricted leaflet motion 0 0 0
Leaflet prolapse 0 0 0
Any regurgitation 2 (6.9) 3 (27.3) 32 (20.5)
Regurgitation seen in two views 2 (6.9) 2 (18.2) 28 (17.9)
Jet length ≥1 cm‡ 1 (3.5) 3 (27.3) 29 (18.6)
Velocity ≥3 m/s in early diastole§ 0 1 (9.1) 6 (3.9)
Pandiastolic jet (colour Doppler) 0 2 (18.2) 20 (12.8)

** Congenital mitral valve or aortic valve abnormalities were excluded.

† Abnormal thickening of the anterior mitral valve leaflet ≥3 or >4 mm using harmonic imaging.

‡ In at least 1 view.

§ Measurements available with the Vivid-Q exams.